# European MCL Elderly (NCT00209209)

> Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL

No report yet. It can be ordered.

- Drugs tested: rituximab; R-FC
- Indication: mantle cell lymphoma in elderly patients

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT00209209
- Phase: PHASE3
- Status: UNKNOWN
- Sponsor: European Mantle Cell Lymphoma Network
- Conditions: Lymphoma, Mantle-Cell
- Interventions: Rituximab; Cyclophosphamide; Doxorubicin; Vincristine; Prednisone; Fludarabine; Interferon-alpha; pegylated formula Interferon-alpha 2b; chemotherapy: R-CHOP; chemotherapy: R-FC; Interferon maintenance; Rituximab maintenance
- Enrollment: 570
- Primary outcome: First randomisation: Reduction of lymphoma mass measured by the complete remission (CR) rate
- Primary outcome: Second randomisation: progression-free survival after end of initial chemotherapy

## Indexed commentary on European MCL Elderly so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 2
- YouTube: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=european-mcl-elderly-nct00209209